Latest papers

Effect of bromocriptine on antipsychotic drug-induced hyperprolactinemia: eight-week randomized, single-blind, placebo-controlled, multicenter study.

Congestion as a therapeutic target in acute heart failure syndromes.

Characteristics of progesterone changes in women with subtle progesterone rise in recombinant follicle-stimulating hormone and gonadotropin-releasing hormone antagonist cycle.

Comparative efficacy of bromocriptine, cabergoline and thyroxine in inducing oestrus in bitches.

[The impact of early developmental impairment of the receptor-dependent glucocorticoid action on the pituitary adrenal axis activity and behavior of male rats].

Eight-year follow-up of a child with a GH/prolactin-secreting adenoma: efficacy of pegvisomant therapy.

Inhibition of the progesterone nuclear receptor during the bone linear growth phase increases peak bone mass in female mice.

A new treatment option for type 2 diabetes.

Dienogest: a new therapeutic agent for the treatment of endometriosis.

Endocrine therapies and QTc prolongation.

Mifepristone and spironolactone differently alter cocaine intravenous self-administration and cocaine-induced locomotion in C57BL/6J mice.

A potential gastrointestinal link between enhanced postnatal maternal care and reduced anxiety-like behavior in adolescent rats.

Ischemic preconditioning attenuates gastric ischemia-reperfusion injury through involvement of glucocorticoids.

Metastatic cancer in solid tumors and clinical outcome: skeletal-related events.

Early breast and prostate cancer and clinical outcomes (fracture).

Neuropsychological functioning in health and mood disorder: Modulation by glucocorticoids and their receptors.

[Increased risk of early pregnancy loss and lower live birth rate with GNRH antagonist vs. long GNRH agonist protocol in PCOS women undergoing controlled ovarian hyperstimulation].

Pegvisomant: current and potential novel therapeutic applications.

Cisplatin cytotoxicity is increased by mifepristone in cervical carcinoma: an in vitro and in vivo study.

[Vasopressin receptor antagonists and heart failure].